What do systematic reviews say?

Any early psychological intervention vs active control

• Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 414 participants
  Low

Any early psychological intervention vs active control

• Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 239 participants
  Low

Any early psychological intervention vs inactive control (usual care care, attention control, waitlist)

Any early psychological intervention may leads to lower PTSD diagnosis: 3–6 months compared with waiting list/usual care (low certainty).

• Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder 2019 · Cochrane Headline outcomes only
  RR 0.62 [0.41, 0.93]
  5 studies · 758 participants
  Low
• Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder 2019 · Cochrane Headline outcomes only
  RR 0.94 [0.2, 4.49]
  1 study · 132 participants
  Very low

Any early psychological intervention vs inactive control (usual care care, attention control, waitlist)

Any early psychological intervention showed no clear difference in dropouts from treatment compared with waiting list/usual care (low certainty).

• Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder 2019 · Cochrane Headline outcomes only
  RR 1.34 [0.91, 1.95]
  11 studies · 1154 participants
  Low

Any early psychological intervention vs inactive control (usual care care, attention control, waitlist)

• Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder 2019 · Cochrane Headline outcomes only
  no estimate extracted
  15 studies · 1921 participants
  Low

Any early psychological intervention vs inactive control (usual care care, attention control, waitlist)

• Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 1009 participants
  Low

Any early psychological intervention vs inactive control (usual care care, attention control, waitlist)

• Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder 2019 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 945 participants
  Low

Any early psychological intervention vs active control

Any early psychological intervention may leads to higher dropouts from treatment compared with active control condition (low certainty).

• Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder 2019 · Cochrane Headline outcomes only
  RR 1.61 [1.11, 2.34]
  2 studies · 425 participants
  Low

Any early psychological intervention vs active control

• Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder 2019 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 465 participants
  Low

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

Switching to mianserin (60 mg/d) showed no clear difference in depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 71 participants
  Low

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 431 participants
  High

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  RR 0.5 [0.15, 1.62]
  1 study · 480 participants
  High

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in response (≥ 50% improvement in BDI‐II score) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  RR 1.22 [0.97, 1.54]
  1 study · 431 participants
  High

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in remission (BDI‐II total score ≤ 9) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  RR 1.21 [0.88, 1.65]
  1 study · 431 participants
  High

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 447 participants
  High

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 102 participants
  Low

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Augmentation of current antidepressant (SSRI) with busiprone (20… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI) with placebo (low certainty).

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  RR 0.6 [0.23, 1.53]
  1 study · 108 participants
  Low

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found